234 related articles for article (PubMed ID: 27213997)
21. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
[TBL] [Abstract][Full Text] [Related]
22. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
23. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
[TBL] [Abstract][Full Text] [Related]
24. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
25. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
26. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
[TBL] [Abstract][Full Text] [Related]
27. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project.
Uribarri M; Ruiz-Larrañaga O; Arteta D; Hernández L; Alcaro MC; Martínez A; Escorza-Treviño S; Estonba A; Migliorini P; Czirják L; del Amo J
Clin Exp Rheumatol; 2015; 33(5):699-705. PubMed ID: 26314492
[TBL] [Abstract][Full Text] [Related]
28. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
[TBL] [Abstract][Full Text] [Related]
29. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
30. A Cross-sectional Survey on the Preference of Patients with Rheumatoid Arthritis for Route of Administration of Disease-Modifying Anti-Rheumatic Drugs: Oral Target-Specific Versus Parenteral Biologic.
Edel Y; Sagy I; Pokroy-Shapira E; Oren S; Dortort Lazar A; Egbaria M; Shiber S; Tal BS; Molad Y
Isr Med Assoc J; 2020 Mar; 22(3):154-159. PubMed ID: 32147979
[TBL] [Abstract][Full Text] [Related]
31. [Combination therapy using methotrexate with DMARDs or biologics--current status].
Krüger K
Z Rheumatol; 2011 Feb; 70(2):114-22. PubMed ID: 21267733
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
33. A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.
Aaltonen KJ; Sokka T; Möttönen T; Korpela M; Komulainen R; Uusitalo T; Salomaa S; Uutela T; Valleala H; Rami Study Group
Scand J Rheumatol; 2014; 43(4):286-90. PubMed ID: 24654994
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients.
Bologna C; Jorgensen C; Sany J
Clin Exp Rheumatol; 1997; 15(6):597-601. PubMed ID: 9444414
[TBL] [Abstract][Full Text] [Related]
35. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
Cuppen BV; Jacobs JW; Ter Borg EJ; Marijnissen AC; Bijlsma JW; Lafeber FP; van Laar JM;
Clin Exp Rheumatol; 2017; 35(2):221-228. PubMed ID: 27749223
[TBL] [Abstract][Full Text] [Related]
36. Adherence to Anti-Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis.
Salaffi F; Carotti M; Di Carlo M; Farah S; Gutierrez M
J Clin Rheumatol; 2015 Dec; 21(8):419-25. PubMed ID: 26587852
[TBL] [Abstract][Full Text] [Related]
37. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
Bergman M; De G; Ganguli A; Signorovitch J; Bao Y
J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
[TBL] [Abstract][Full Text] [Related]
38. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate: a gold standard for treatment of rheumatoid arthritis.
Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG
J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199
[TBL] [Abstract][Full Text] [Related]
40. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
